Cancer treatment with epothilones

Details for Australian Patent Application No. 2004268377 (hide)

Owner Novartis AG

Inventors Dilea, Clifford; Wartmann, Markus; McSheehy, Paul M. J.; Tanaka, Chiaki; Maira, Sauveur-Michel

Agent Davies Collison Cave

Pub. Number AU-B-2004268377

PCT Pub. Number WO2005/020989

Priority 60/499,548 02.09.03 US

Filing date 1 September 2004

Wipo publication date 10 March 2005

Acceptance publication date 26 June 2008

International Classifications

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

23 March 2006 PCT application entered the National Phase

  PCT publication WO2005/020989 Priority application(s): WO2005/020989

26 June 2008 Application Accepted

  Published as AU-B-2004268377

23 October 2008 Standard Patent Sealed

24 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004268380-Method of stabilizing ascorbyl phosphate and salts thereof

2004268376-Pharmaceutical formulation comprising a pyrimidine-A-one derivative coated with an enteric polymer